Valeritas Holdings, Inc. Elects Joe Mandato to its Board of Directors, Effective December 1, 2016
November 30, 2016 at 01:30 pm
Share
Valeritas Holdings, Inc. announced the election of Joe Mandato, Ph.D., to the company’s board of directors, effective December 1, 2016. In conjunction with the appointment of Dr. Mandato, Nate Hukill, who represents CRG, will step down from the board of directors as of December 1, resulting in a board with five independent directors on a Board comprising seven members. Dr. Mandato has extensive experience in the medical device industry as an executive, investor, educator and board member and has led numerous companies to commercial success. He is currently a managing director at DeNovo Ventures where he led investments in 10 medical device companies. Prior to joining DeNovo Ventures, Dr. Mandato had extensive operational experience as the chairman or chief executive officer of numerous medical device companies, including, but not limited to Ioptex, Confer Software, Gynecare, and Origin Medsystems.
Valeritas Holdings, Inc. is a United States-based medical technology company. The Company's product, V-Go Wearable Insulin Delivery device (V-Go), is a wearable, basal-bolus insulin delivery device for adult patients requiring insulin that enables patients to administer a continuous preset basal rate of insulin over 24 hours. V-Go is a small wearable and completely disposable insulin delivery device that a patient adheres to his or her skin every 24 hours. V-Go enables patients to closely mimic the body's normal physiologic pattern of insulin delivery throughout the day and to manage their diabetes with insulin without the need to plan a daily routine around multiple daily injections. It has developed V-Go utilizing its h-Patch platform as a patient-focused solution to address insulin therapies. Its h-Patch platform facilitates the subcutaneous delivery of injectable medicines to patients across a range of therapeutic areas.
VALERITAS HOLDINGS, INC. 
